FDA sets PDUFA Action Date of June 28, 2025 ...
Sunvozertinib has shown promising results in patients with non–small cell lung cancer with an EGFR exon 20 insertion mutation ...
The FDA has accepted a new drug application for the glioma-imaging agent Pixclara, with a decision expected next year. The Food and Drug Administration (FDA) has accepted a new drug application for ...
New hope could be on the horizon for ALS patients in the form of a "breakthrough" drug ... This month, Neuvivo submitted a new drug application (NDA) to the U.S. Food and Drug Administration ...
Standard components of the forms include the subject name, subject study number, and the names and contact information of the authorized prescribers of the study drug. The drug name, dosage ...
acceptance of the New Drug Application (NDA) for investigational drug UGN-102 (mitomycin) for intravesical solution. UGN-102 could become the first FDA-approved medicine for the treatment of low ...
Oct. 09, 2024 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class ... New Drug (IND) application from the U.S. Food ...
A new drug for people who have one of the worst forms of multiple sclerosis aims to make treatment much easier for patients. Ocrevus is a medicine commonly used to treat primary progressive MS ...
Somerset West is among the centres that will be forced to close its supervised consumption site by March 31, 2025 under new ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback